High concentrations of parathyroid hormone (PTH) are common in patients with hepatocellular carcinoma (HCC). This study is aimed to investigate effects of vitamin D status and its multiple mega-dosage supplementation on PTH and clinical outcomes in HCC patients before and after hepatectomy. It's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. The subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.
1. ≥ 20-year HCC subjects receiving laparoscopic hepatectomy
2.Sign the informed consent
1. Using estrogen drugs, bisphosphonates, or drugs for bone disease.
2. Consume calcium tablets within 2 weeks before operation
3. Sarcoidosis, multiple myeloma
4. Pregnant women or plan to become pregnant within 3 months after surgery
Parallel
Vitamin D
Other interventionOral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
Placebo
Other interventionOral supplementation of placebo in 3 consecutive days.
Whether there is an association between 25(OH)D and PTH: positive or negative association , or no association
Ratio of liver failure
Ratio of liver failure
Ratio of liver failure
25(OH)D status
Prevalence of high PTH
Prevalence of hypercalcemia
Prevalence of hypomagnesemia
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
